Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Securities lawsuit up against Merck's Vioxx
In April 2007, Federal Judge Stanley Chesler dismissed an investor lawsuit seeking class-action status against Merck, but an appeals panel from the Third U.S. Circuit Court of Appeals reversed the ruling on Tuesday. Plaintiffs filed the original lawsuit in November 2003.
Judge Chesler originally said the statute of limitations was up, but the appeals panel disagreed.
Plaintiffs claim Merck was not straightforward about the risks of Vioxx. The plaintiff investors took a $30-billion dollar hit in 2004 when Merck withdrew Vioxx following news that the drug doubled the risk of heart attack or stroke. The securities lawsuit is distinct from personal injury lawsuits against Merck, which began paying claimants last month.
According to Merck, the statute-of-limitations rationale is not the only rationale for blocking the suit. For example, Merck says there were no strong data linking Vioxx to heart attacks or strokes at the time. The company will seek reversal based on alternative grounds if necessary.
- read the story at CNN Money
- see the Wall Street Journal's take
- here are the court documents
Related Articles:
Judge whacks Vioxx class action suit
NY double-teams Merck in Vioxx lawsuit
Judge throws out $50M Vioxx award
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


